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The high-affinity IgE receptor (Fcε RI) is a heterotetramer of three subunits: Fcε RIα,
Fcε RIβ, and Fcε RIγ (αβγ2) encoded by three genes designated as FCER1A, FCER1B
(MS4A2), and FCER1G, respectively. Recent evidence points to FCERI gene variability
as a relevant factor in the risk of developing allergic diseases. Because Fcε RI plays a
key role in the events downstream of the triggering factors in immunological response,
we hypothesized that FCERI gene variants might be related with the risk of, or
with the clinical response to, selective (IgE mediated) non-steroidal anti-inflammatory
(NSAID) hypersensitivity. From a cohort of 314 patients suffering from selective
hypersensitivity to metamizole, ibuprofen, diclofenac, paracetamol, acetylsalicylic acid
(ASA), propifenazone, naproxen, ketoprofen, dexketoprofen, etofenamate, aceclofenac,
etoricoxib, dexibuprofen, indomethacin, oxyphenylbutazone, or piroxicam, and 585
unrelated healthy controls that tolerated these NSAIDs, we analyzed the putative
effects of the FCERI SNPs FCER1A rs2494262, rs2427837, and rs2251746; FCER1B
rs1441586, rs569108, and rs512555; FCER1G rs11587213, rs2070901, and rs11421.
Furthermore, in order to identify additional genetic markers which might be associated
with the risk of developing selective NSAID hypersensitivity, or which may modify the
putative association of FCERI gene variations with risk, we analyzed polymorphisms
known to affect histamine synthesis or metabolism, such as rs17740607, rs2073440,
rs1801105, rs2052129, rs10156191, rs1049742, and rs1049793 in the HDC, HNMT,
and DAO genes. No major genetic associations with risk or with clinical presentation,
and no gene-gene interactions, or gene-phenotype interactions (including age, gender,
IgE concentration, antecedents of atopy, culprit drug, or clinical presentation) were
identified in patients. However, logistic regression analyses indicated that the presence
of antecedents of atopy and the DAO SNP rs2052129 (GG) were strongly related (P
< 0.001 and P = 0.005, respectively) with selective hypersensitivity to ibuprofen. With
regard to patients with selective hypersensitivity to ASA, menweremore prone to develop
such a reaction than women (P = 0.011), and the detrimental DAO SNP rs10156191 in
homozygosity increased the risk of developing such hypersensitivity (P = 0.039).
Keywords: Fcε RI, histamine, non-steroidal anti-inflammatory drugs (NSAIDS), hypersensitivity drug reactions,
biomarkers
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INTRODUCTION
Type B drug-induced hypersensitivity reactions (DHR) occur
only in susceptible individuals with a frequency of 5–10%
of all adverse drug reactions (Khan and Solensky, 2010). In
general, these reactions are severe and occasionally may be life-
threatening. In recent years evidence has accumulated to support
the notion that DHR may be caused by various mechanisms
and is the result of a complex multifactorial and multigenic
process (Pirmohamed, 2006). Regarding culprit drugs, non-
steroidal anti-inflammatory drugs (NSAIDs) are among the most
frequent causes of DHR together with antibiotics (Cornejo-
Garcia et al., 2009; Doña et al., 2011, 2012; Kowalski et al.,
2011). Hypersensitivity reactions to a single NSAID (selective
reactions) are the result of an immunological mechanism, which
is either IgE-mediated in acute reactions or T cell-mediated
in delayed reactions. Clinical manifestations include cutaneous
reactions, respiratory reactions and anaphylaxis, which may
appear with different onset times after drug intake. Histamine
release from mast cells after IgE receptor activation plays a
relevant role in allergic inflammation and in the development
of clinical symptoms (Mita et al., 2001; Kowalski et al.,
2011).
A priori, genetic variations affecting both components
(expression and/or function) of this signaling pathway, including
high affinity IgE receptor and histamine metabolizing enzymes,
could modify the risk of developing hypersensitivity to NSAIDs,
and/or the presentation of clinical manifestations. In fact, recent
studies have demonstrated an association between several allergic
diseases including drug hypersensitivity and polymorphisms in
these genes (García-Martín et al., 2006, 2007a; Kennedy et al.,
2008; Gervasini et al., 2010; Maintz et al., 2011).
The high-affinity IgE receptor (Fcε RI) is a heterotetramer of
three subunits: Fcε RIα, Fcε RIβ, and Fcε RIγ (αβγ2) encoded
by three genes designated as FCER1A, FCER1B (MS4A2),
and FCER1G, respectively. The genes coding for all FcεRI
subunits are polymorphic and some of these polymorphisms
have been associated with several atopic diseases (MacGlashan
et al., 1998, 1999; Saini et al., 1999; Weidinger et al., 2008;
Zhang et al., 2010; Li et al., 2014). The FCER1A gene is
located on chromosome 1q23 (1:159259504-159278014;
1000 Genomes, 2015), and it encodes a protein with two
extracellular IgE-like domains with ligand-binding sites
(Potaczek and Kabesch, 2012). The FCER1B gene is located
on chromosome 11q12-13 (11:59855734–59863444; 1000
Genomes, 2015), and it encodes a 244-amino acid protein with
a non-canonic intracellular ITAM domain. Functionally, it is
a signal-augmenting subunit. The FCER1G gene is located on
chromosome 1q23 (1:161185024–161190489; 1000 Genomes,
2015) and encodes an 86-amino acid protein. Functionally, it is
a signal-transducing subunit and plays an essential role in the
induction of mast cell degranulation and survival (Manikandan
et al., 2012).
With regard to histamine homeostasis, histamine biosynthesis
is catalyzed by the enzyme L-histidine decarboxylase (HDC,
E.C. 4.1.1.22). Two enzymes participate in the degradation
of histamine: Histamine N-methyltransferase (HNMT, E.C.
2.1.1.8) and diamine oxidase (DAO; E.C. 1.4.3.6; García-
Martín et al., 2009). There is high individual variability in
histamine metabolism which is, at least in part, genetically
determined, although other factors, such as gender (García-
Martín et al., 2007b) play a major role in the variability of
histamine metabolism. An association between polymorphisms
of histamine metabolizing enzymes and the clinical presentation
of allergic diseases has been demonstrated (García-Martín et al.,
2006, 2007a; Kennedy et al., 2008; Gervasini et al., 2010; Maintz
et al., 2011).
The HDC gene is located in chromosome 15q21-q22 and
spans around 24 kilobases. The HNMT gene is located in
chromosome 2q22.1. The human DAO gene spans ∼10 kb
and is located in chromosome 7q34-q36. A promoter SNP and
three common non-synonymous SNPs have been identified in
Caucasian individuals, and the functional effects of these SNPs
in enzyme activity have been studied in detail (Ayuso et al., 2007;
García-Martín et al., 2007b).
In order to investigate the role of genetic factors in the risk
of developing selective NSAID hypersensitivity, both isolated
and combined, given that the clinical outcome depends on
the interplay of IgE response and the consequent release of
mediators, in this study we analyzed functional polymorphisms
in high affinity IgE receptors and genes related to histamine
metabolism in a large group of well-phenotyped patients
suffering from single-NSAID-induced hypersensitivity reactions.
Our aim was to elucidate the putative association of these
gene polymorphisms with several clinical phenotype parameters,
including gender, age, antecedents of atopy, culprit drug, IgE
levels and clinical presentation, and to analyze putative gene-
gene interactions. The final goal was to identify biomarkers
which alone or combined with pharmacogenomics or metabolic
biomarkers (Agúndez et al., 2009a,b, 2015; Cornejo-García et al.,
2012; Martinez et al., 2014; García-Martín et al., 2015a; Ariza
et al., 2016) might be useful in prevention, diagnosis and/or
proper management of these patients.
PATIENTS AND METHODS
Study Population
We studied a cohort of 899 individuals, consisting of 314
unrelated Spanish patients with single-NSAID-induced
hypersensitivity reactions and 585 unrelated healthy controls.
Written consent for participation was obtained for all
participants. All the patients who were invited to participate in
the study agreed to do so. Of the patients, 145 were recruited
from the Allergy service, Hospital Infanta Leonor (Madrid,
Spain), 100 were recruited from the Allergy service, Regional
Hospital (Málaga, Spain) and 69 were recruited from the
Allergy Department, Infanta Cristina Hospital (Badajoz, Spain).
Diagnosis was carried out as previously described (Doña et al.,
2011). After confirming good tolerance to a full therapeutic dose
of ASA, incremental doses of the culprit drug were given until
the therapeutic dose for the analgesic/NSAIDs implicated in the
study was achieved. In the case of selective responses to ASA,
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confirmation of the selective response was made by challenge
with indomethacin as reported elsewhere (Doña et al., 2011).
Participants’ characteristics are summarized in Table 1. The
NSAIDs responsible for the reaction are summarized in Table 2.
Clinical presentation distributed according to gender and culprit
drug are shown in Table 3.
The healthy controls were recruited from staff and medical
students of the Hospitals and the Universities participating in
the study, and were ethnically matched with patients (all were
unrelated Spanish individuals). All control subjects tolerated the
NSAIDs most frequently involved in selective hypersensitivity, as
shown in Table 2. Specifically, all control individuals previously
received metamizole, ibuprofen, diclofenac, paracetamol, and
ASA, and experienced no hypersensitivity or other ADRs.
Individuals with the above-mentioned characteristics were asked
TABLE 1 | Characteristics of the study group.
Patients
(n = 314)
Healthy subjects
(n = 585)
Women, n (%) 205 (65.3) 356 (60.8)
Age [SD; range] 45.4 [16.1; 5–82] 22.3 [4.8; 20–57]
Antecedents of atopy, n (%) 66 (21.0) 0
Antecedents of urticaria, n (%) 4 (1.3) 0
Interval <1 h; n (%), Single NSAID-induced
urticaria/angioedema, and anaphylaxis
232 (73.9) n.a.
Interval >24 h; n (%), Single
NSAID-induced delayed reaction
13 (4.1) n.a.
Interval unknown, n (%) 69 (22.0) n.a.
TABLE 2 | Culprit drug for selective NSAID-induced hypersensitivity.
Culprit drug Total PATIENTS DISTRIBUTED
No. (%) BY GENDER
Men (No. %) Women (No. %)
Metamizole 108 (34.4) 32 (29.3) 76 (37.1)
Ibuprofen 94 (29.9) 35 (32.1) 59 (28.8)
Diclofenac 35 (11.1) 15 (13.8) 20 (9.8)
Paracetamol 20 (6.4) 7 (6.4) 13 (6.3)
Acetyl salicylic acid 19 (6.1) 8 (7.3) 11 (5.4)
Propifenazone 12 (3.8) 4 (3.7) 8 (3.9)
Naproxen 9 (2.9) 3 (2.8) 6 (2.9)
Ketoprofen 3 (1.0) 0 3 (1.5)
Dexketoprofen 3 (1.0) 2 (1.8) 1 (0.5)
Etofenamate 3 (1.0) 1 (0.9) 2 (1.0)
Aceclofenac 1 (0.3) 1 (0.9) 0
Etoricoxib 1 (0.3) 0 1 (0.5)
Dexibuprofen 1 (0.3) 0 1 (0.5)
Indomethacin 1 (0.3) 0 1 (0.5)
Oxyphenbutazone 1 (0.3) 0 1 (0.5)
Piroxicam 1 (0.3) 0 1 (0.5)
Unknown 2 (0.6) 1 (0.9) 1 (0.5)
Total 314 (100) 109 (100) 205 (100)
to participate, and 97% of them agreed. A medical history was
obtained and an examination was performed for each participant
to exclude pre-existing disorders. Individuals with familial (up
to second-degree relatives) or personal antecedents of allergic,
atopic, or autoimmune diseases were excluded from the control
group to avoid confounders. The protocol for this study was in
accordance with the Declaration of Helsinki and its subsequent
revisions and was approved by the respective Ethics Committees
of the participating Hospitals.
Genotype Analysis
Genomic DNA was obtained from peripheral leukocytes and
purified in accordance with standard procedures. The SNPs
analyzed were selected according to allele frequencies (over
0.01) in the study population, and either functional or clinical
relevance, in line with published evidence (Preuss et al., 1998;
García-Martín et al., 2006, 2007a, 2009; Ayuso et al., 2007; Maintz
et al., 2011; Amo et al., 2016), and the public 1000 genomes
database release of 17 Nov. 2015. Genotyping was performed by
TaqMan assays (Life Technologies, Alcobendas, Madrid, Spain).
Details of the TaqMan probes and the allele frequencies in
Caucasian individuals are summarized in Table 4. We studied
nine FCER1 SNPs, as well as SNPs corresponding to genes
involved in histamine synthesis (HDC) or metabolism (HNMT
and DAO). All these histamine-related SNPs have demonstrated
functional and/or clinical implications (García-Martín et al.,
2006, 2007a,b, 2009, 2015b; Ayuso et al., 2007; Gervasini et al.,
2010; Agúndez et al., 2012).
Detection was carried out by means of real-time PCR
(qPCR) in an Eppendorf realplex thermocycler using fluorescent
probes. The amplification conditions were as follows: After a
denaturation time of 10 min at 96◦C, 45 cycles of 92◦C 15 s
60◦C 90 s were carried out and fluorescence was measured at the
end of each cycle and at endpoint. All samples were determined
in triplicate and genotypes were assigned both by means of
gene identification software (RealPlex 2.0, Eppendorf), and by
analysis of the reference cycle number for each fluorescence
curve, calculated using the CalQPlex algorithm (Eppendorf).
Statistical Analyses
Statistical power for each SNPwas evaluated with a genetic model
to analyze the frequency for the minor allele with an odds ratio
(OR) value = 1.5 (α = 0.05) based on the allele frequencies
observed in the control group.Table 4 shows the statistical power
for each SNP analyzed. For most SNPs the statistical power
was very high. In some cases, because of the low minor allele
frequency observed, the statistical power was not sufficient to
detect an OR = 1.5 but was sufficient to detect an OR = 2.0 with
a bilateral power of more than 80% (Table 4), with the single
exception of the HDC SNP rs2073440 T/G, whose power was
sufficient to detect an OR= 2.1.
SNPStats software (Solé et al., 2006) was used to calculate
allele and genotype frequencies, to analyze the Hardy-Weinberg
equilibrium, and to determine linkage disequilibrium statistics
and haplotype frequency estimation. Multiple comparison
adjustment was done by using the False Discover Rate
(FDR) correction (http://www.sdmproject.com/utilities/?show=
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TABLE 3 | Clinical presentation of selective NSAID-induced hypersensitivity.
Gender Urticaria +
Angioedema
(No. %)
Anaphylaxis
(No. %)
Exanthema
(No. %)
Mixed pattern
(No. %)
Respiratory
(No. %)
Toxic hepatitis
(No. %)
Unknown
(No. %)
Total
(No. %)
PATIENTS DISTRIBUTED BY CLINICAL PRESENTATION
Men 57 (52.3) 40 (36.7) 9 (8.3) 2 (1.8) 0 0 1 (0.9) 109 (100)
Women 113 (55.1) 68 (33.2) 10 (4.9) 7 (3.4) 5 (2.4) 1 (0.5) 1 (0.5) 205 (100)
Culprit drug Urticaria +
Angioedema
(No. %)
Anaphylaxis
(No. %)
Exanthema
(No. %)
Mixed pattern
(No. %)
Respiratory
(No. %)
Toxic hepatitis
(No. %)
Unknown
(No. %)
Total
(No. %)
Metamizole 45 (41.7) 53 (49.1) 7 (6.5) 3 (2.8) 0 0 0 108 (100)
Ibuprofen 70 (74.5) 18 (19.1) 2 (2.1) 3 (3.2) 1 (1.1) 0 0 94 (100)
Diclofenac 13 (37.1) 20 (57.1) 2 (5.7) 0 0 0 0 35 (100)
Paracetamol 12 (60.0) 5 (25.0) 1 (5.0) 0 2 (10.0) 0 0 20 (100)
Acetyl Salicylic Acid 13 (68.4) 1 (5.3) 2 (10.5) 0 2 (10.5) 0 1 (5.3) 19 (100)
Propifenazone 6 (50.0) 4 (33.3) 1 (8.3) 1 (8.3) 0 0 0 12 (100)
Naproxen 4 (44.4) 2 (22.2) 1 (11.1) 2 (22.2) 0 0 0 9 (100)
Ketoprofen 2 (66.7) 0 0 0 0 1 (33.3) 0 3 (100)
Dexketoprofen 1 (33.3) 2 (66.6) 0 0 0 0 0 3 (100)
Etofenamate 2 (66.7) 0 1 (33.3) 0 0 0 0 3 (100)
Aceclofenac 0 1 (100) 0 0 0 0 0 1 (100)
Etoricoxib 1 (100) 0 0 0 0 0 0 1 (100)
Dexibuprofen 0 1 (100) 0 0 0 0 0 1 (100)
Indomethacin 0 0 1 (100) 0 0 0 0 1 (100)
Oxyphenbutazone 0 0 0 0 0 0 1 (100) 1 (100)
Piroxicam 1 (100) 0 0 0 0 0 0 1 (100)
Unknown 0 1 (50) 1 (50) 0 0 0 0 2 (100)
Total 170 108 19 9 5 1 2 314
TABLE 4 | SNPs analyzed in this study.
Gene Chromosomal
location
dbSNP Consequence Assay ID MAF (1000 genomes,
European individuals)
Statistical power (two tailed,
OR = 1.5, α =0.05)* (%)
FCER1A 1:159253672 rs2494262 A/C Upstream gene C____494924_20 0.44 C 98
FCER1A 1:159258545 rs2427837 G/A Upstream gene C__16233438_20 0.30A 96
FCER1A 1:159272060 rs2251746 T/C Intronic Custom-designed 0.30 C 96
FCER1B 11:59856028 rs1441586 T/C 5 prime UTR C___1842226_10 0.46 C 98
FCER1B 11:59863104 rs569108 A/G Missense 237 E/G C____900116_10 0.04 G 36 (a)
FCER1B 11:59863253 rs512555 C/T 3 prime UTR C___7513065_10 0.04 T 37 (b)
FCER1G 1:161184875 rs11587213 A/G Upstream gene C__27848237_10 0.18 G 88
FCER1G 1:161185058 rs2070901 G/T Non-coding transcript exon C__15867981_20 0.27 T 97
FCER1G 1:161188936 rs11421 T/C 3 prime UTR C___1841966_1_ 0.15 C 91
HNMT 2:138759649 rs11558538 C/T Missense 105 T/I C__11650812_20 0.10 T 73 (c)
DAO 7:150548972 rs2052129 G/T Upstream gene C__11630976_1 0.25 T 97
DAO 7:150553605 rs10156191 C/T Missense 16 T/M C__25593951_10 0.27 T 96
DAO 7:150554553 rs1049742 C/T Missense 332 S/F C___7599782_20 0.08 T 58 (d)
DAO 7:150557665 rs1049793 C/G Missense 645 H/D C___7599774_10 0.27 G 97
HDC 15:50534514 rs2073440 T/G Missense 644 E/D C__15950871_20 0.02 G 31 (e)
HDC 15:50555544 rs17740607 G/A Missense 31 T/M C__25624415_20 0.10A 69 (f)
*The statistical power (two tailed, OR = 2.0, α = 0.05) is as follows: (a) 82%; (b) 83%; (c) 100%; (d) 97%; (e) 75%; (f) 99%. MAF, Minor allele frequency.
Frontiers in Pharmacology | www.frontiersin.org 4 September 2016 | Volume 7 | Article 353
Amo et al. Gene Variability in NSAIDs HR
FDR). Analyses of association with a response variable (culprit
drugs and reactions) based on logistic regression were performed
using SPSS 21.0 for Windows. For these analyses, we also
determined the odds ratio and the corresponding 95% confidence
intervals. The Hosmer-Lemeshow goodness of fit test for
logistic regression was used. For the IgE response variable a
multiple linear regression model was calculated. The results were
considered as statistically significant when the p-value was less
than 0.05.
RESULTS
The percentage of women was slightly higher in the cases,
as compared to the control individuals (Table 1), although no
statistically significant gender differences between cases and
controls were present (Chi-square P = 0.191). Conversely, age
was lower in the controls than in the cases. However, age is not
a key factor in this study, as all the control individuals were
tolerant to NSAIDs and the odds are extremely low that they may
eventually develop selective NSAID-induced hypersensitivity.
The most common culprit drugs for selective NSAID-
induced hypersensitivity were metamizole, ibuprofen, diclofenac,
paracetamol, and ASA (Table 2). Although the frequency for
metamizole-induced hypersensitivity was higher in women than
in men, OR= 1.42 and 95% confidence interval (CI) 0.84–2.41; P
= 0.171, the frequency difference was not statistically significant,
and neither were the differences for gender-related frequencies
for the rest of the NSAIDs included in Table 2. These frequencies
correspond to those previously described by our group (Doña
et al., 2011; Blanca-López et al., 2016a,b).
The most frequent clinical presentation was urticaria +
angioedema, followed by anaphylaxis, exanthema and mixed
pattern. No gender-related differences in clinical presentation
were observed (Table 3). Clinical presentation, however, was
strongly related with the culprit drug: The clinical presentation
urticaria + angioedema was particularly frequent when the
culprit drug was ibuprofen (OR = 3.50, 95% CI = 1.99–6.19);
P <0.001. In contrast, when the causative drug was metamizole
or diclofenac, the most common clinical presentation was
anaphylaxis (OR = 2.65, 95% CI = 1.58–4.44; P < 0.001) and
(OR= 2.89, 95% CI= 1.34–6.28, P = 0.003), respectively. When
the culprit drug was paracetamol or ASA the most frequent
presentation was urticaria+ angioedema, although for these two
drugs the association of the drug with clinical presentation was
not statistically significant. These phenotypic features correspond
to those previously reported for selective NSAID hypersensitivity
patients (Cornejo-Garcia et al., 2009; Doña et al., 2011; García-
Martín et al., 2015a).
FCER1 genotyping results are summarized in Table 5. We
checked the codominant, dominant, recessive, overdominant and
additive models and the best fit was obtained with the recessive
model. FCER1 SNPs did not show statistically significant
differences when patients and controls were compared in any
of the genetic models analyzed. The genotyping results related
to histamine synthesis and metabolism genes are summarized in
Table 6. Once again, the best fit for histamine metabolism genes
was obtained with the recessive model. Statistically significant
differences on comparing cases and control subjects were
identified for the DAO SNP rs10156191, which caused decreased
enzyme activity (Ayuso et al., 2007). The observed difference
was related to the frequency of homozygous individuals for the
minor allele, which obtained a marginal significance that was not
observed when the allele frequency (instead of the genotypes)
was analyzed. When correction for multiple comparisons was
carried out by using FDR, the P value for the recessive model
for the DAO rs10156191 SNP was not significant (corrected P =
0.294), whereas the P-value for carriers of the minor allele for the
HDC SNP rs2073440 remained significant (corrected P-value =
0.021).
Table 7 shows the statistically significant interaction of the
genotypes studied and gender. The association of the FCER1A
SNP rs2427837 with the risk of developing NSAID-induced
hypersensitivity showed a positive interaction with gender, the
association being stronger in women (Table 7). A statistically
significant, genotype-gender interaction was observed for two
other FCER1 genotypes (rs2251746 in women and rs11587213
in men). When FDR correction for multiple comparisons (both
genders and all SNPs) wasmade, the corrected P-values remained
TABLE 5 | FCER1 SNPs analyzed in this study.
Gene Chromosomal
location
dbSNP Cases non-
mutated/
heterozygous/
homozygous
Cases
MAF
Control non-
mutated/
heterozygous/
homozygous
Control
MAF
Comparison values (recessive
model; OR, 95% CI)
Comparison values (carrier
of the minor allele; OR,
95% CI)
FCER1A 1:159253672 rs2494262 83/146/73 0.483 136/260/107 0.471 1.12 (0.75–1.67); P = 0.589 1.05 (0.86–1.29); P = 0.633
FCER1A 1:159258545 rs2427837 181/101/17 0.226 297/212/38 0.263 0.73 (0.40–1.34); P = 0.312 0.82 (0.65–1.03); P = 0.089
FCER1A 1:159272060 rs2251746 185/107/14 0.221 300/221/34 0.260 1.22 (0.82–1.81); P = 0.337 1.10 (0.90–1.34); P = 0.350
FCER1B 11:59856028 rs1441586 82/148/71 0.482 160/275/114 0.458 1.22 (0.82–1.81); P = 0.337 1.10 (0.90–1.34); P = 0.350
FCER1B 11:59863104 rs569108 274/21/1 0.039 517/39/0 0.035 5.66 (0.23–139.3; P = 0.170 1.11 (0.66–1.88); P = 0.690
FCER1B 11:59863253 rs512555 290/22/1 0.038 530/39/0 0.034 5.48 (0.22–134.9); P = 0.177 1.12 (0.67–1.89); P = 0.660
FCER1G 1:161184875 rs11587213 219/79/15 0.174 408/150/16 0.159 1.75 (0.85–3.60); P = 0.126 1.12 (0.86–1.45); P = 0.400
FCER1G 1:161185058 rs2070901 164/124/25 0.278 285/231/52 0.294 0.84 (0.50–1.40); P = 0.493 0.92 (0.74–1.14); P = 0.453
FCER1G 1:161188936 rs11421 217/85/10 0.168 390/157/24 0.180 0.75 (0.35–1.60); P = 0.452 0.93 (0.71–1.20); P = 0.553
Three hundred and fourteen cases and 585 control individuals were included in the study. The sum of genotypes do not correspond to all cases and controls because of DNA shortage.
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TABLE 6 | SNPs related with histamine synthesis and degradation analyzed in this study.
Gene Chromosomal
location
dbSNP Cases non-
mutated/
heterozygous/
homozygous
Cases
MAF
Control
non-mutated/
heterozygous/
homozygous
Control
MAF
Comparison values
(recessive model; OR,
95% CI)
Comparison values
(carrier of the minor
allele; OR, 95% CI)
HNMT 2:138002079 rs11558538 260/51/2 0.088 466/95/7 0.096 0.51 (0.11–2.48); P = 0.398 0.91 (0.65–1.28); P = 0.580
DAO 7:150851884 rs2052129 173/118/14 0.239 322/204/30 0.237 0.87 (0.45–1.68); P = 0.676 1.02 (0.80–1.27); P = 0.928
DAO 7:150856517 rs10156191 178/122/13 0.236 304/214/43 0.267 0.52 (0.27–0.99); P = 0.042 0.85 (0.68–1.06); P = 0.160
DAO 7:150857465 rs1049742 277/34/1 0.058 483/68/2 0.065 0.87 (0.08–9.66); P = 0.911 0.88 (0.58–1.33); P = 0.540
DAO 7:150860577 rs1049793 160/123/28 0.288 292/220/51 0.290 1.00 (0.61–1.65); P = 0.994 1.01 (0.81–1.25); P = 0.940
HDC 15:50242317 rs2073440 289/16/1 0.029 354/25/0 0.033 3.67 (0.15–90.52); P = 0.269 0.44 (0.26–0.77); P = 0.003
HDC 15:50263347 rs17740607 255/53/3 0.095 346/68/8 0.100 0.51 (0.13–1.94); P = 0.313 0.95 (0.67–1.35); P = 0.770
Three hundred and fourteen cases and 585 control individuals were included in the study. The sum of genotypes do not correspond to all cases and controls because of DNA shortage.
TABLE 7 | Statistically significant gender-related risk associations.
Gene Chromosomal
location
dbSNP Gender Cases
MAF
Control
MAF
Comparison values (recessive
model; OR, 95% CI)
Comparison values (carrier of the minor
allele; OR, 95% CI)
FCER1A 1:159258545 rs2427837 Women 0.198 0.279 0.64 (0.28–1.46); P = 0.280 0.64 (0.46–0.89); P = 0.007
FCER1A 1:159272060 rs2251746 Women 0.196 0.271 0.68 (0.28–1.63); P = 0.380 0.65 (0.47–0.91); P = 0.010
FCER1G 1:161184875 rs11587213 Men 0.229 0.129 2.42 (0.74–7.93); P = 0.135 2.01 (1.26–3.19); P = 0.003
significant: P = 0.045 for the genetic associations with the
SNPs rs2427837 and rs2251746 and P = 0.035 for the SNP
rs11587213.
Logistic regression analyses were carried out with separate
models for each clinical presentation, as shown in Table 3,
by comparing between cases all genotypes, gender, age, IgE
concentration, and antecedents of atopy. In addition, we analyzed
putative associations with response, stratifying patients into
two groups: Single NSAID-induced urticarial/angioedema or
anaphylaxis (SNIUAA) and single NSAID-induced delayed
reactions (SNIDR). No significant associations were identified.
In addition, logistic regression analyses were carried out with
separate models for each culprit drug (only drugs with 19 or
more cases were included, as shown in Table 2), by comparing
between cases all genotypes, gender, age, IgE concentration, and
antecedents of atopy.
For ibuprofen, the Hosmer–Lemeshow (HL) goodness of fit
test was equal to 0.80 and revealed that age [P = 0.032; OR
(95% CI) = 0.91 (0.83–0.99)], the presence of atopy antecedents
[P < 0.001; OR = 19.61 (4.13–90.90)] and the DAO SNP
rs2052129 (GG); [P = 0.005; OR = 13.25 (2.14–81.84)] were
related to the risk of developing hypersensitivity. With regard
to metamizole, although linear regression analysis suggested
association with the absence of atopy (P = 0.008; OR = 5.80,
95% CI = 1.58–21.28), the HL goodness of fit test was equal
to 0.001, and therefore the significance of these findings is
limited. For ASA, we identified significant associations with
the SNPs rs10156191 (TT) [P = 0.035, OR = 44.59; 95% CI
= 1.22–1630.56] and with gender (for men, P = 0.011, OR
= 25.64; 95% CI = 2.13–333.33) with an HL goodness of fit
test equal to 0.957. No significant associations were observed
with paracetamol or diclofenac. IgE levels did not show any
association with phenomic or genomic markers. We did not
identify any additional significant associations, although we
cannot rule out association with other culprit drugs because
the subgroup sizes were not sufficiently large to reach statistical
significance.
DISCUSSION
NSAID-induced hypersensitivity type B adverse reactions
are mediated by immunological and non-immunological
mechanisms. Two major clinical phenotypes have been
described: Selective NSAID hypersensitivity, which is drug-
specific and an IgE-mediated mechanism, and cross-intolerance
in which chemically non-related NSAIDs induce the reaction
(Kowalski et al., 2013). Because selective hypersensitivity is
an IgE-mediated mechanism, we analyzed genetic variations
at the high-affinity IgE receptor, which has been shown to
be related with allergic disorders (MacGlashan et al., 1998,
1999; Saini et al., 1999; Weidinger et al., 2008; Zhang et al.,
2010; Li et al., 2014; Amo et al., 2016). It is to be noted
that, despite the large body of published evidence supporting
association of FCER1 SNPs with allergic diseases, this is the
first study to analyze the putative role of FCER1 SNPs in
selective NSAID hypersensitivity. In addition, we previously
identified genetic factors related to cross intolerance (Agúndez
et al., 2012) and, of these, one non-synonymous DAO gene
variation, designated as rs10156191, was overrepresented
among cross-intolerant patients, thus providing the basis for
a detailed study on the role of genetic variations in histamine
metabolism in patients with selective hypersensitivity to
NSAIDs.
FCER1 genotypes have been linked to ASA-intolerant
asthma. In a study carried out on 126 Korean patients with
ASA-intolerant asthma, Palikhe and co-workers analyzed six
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FCER1 SNPs, five of which were also analyzed in our study
(Palikhe et al., 2008a,b). They identified a weak association
of the FCER1G rs11587213 SNP with ASA-intolerant asthma,
the patients showing increased frequency for the AA genotype.
The same study reported an association of the two FCER1A
SNPs rs2427827 and rs2251746 with specific IgE levels and an
association of the FCER1G SNP 11587213 with both total IgE and
specific IgE levels.
Our findings do not support an association of these FCER1A
genotypes with the risk of developing selective hypersensitivity
to ASA, or any other NSAID included in this study, and neither
do they support an association with total IgE levels. Potential
discrepancies between our study and that of Palikhe and co-
workers may arise from the differences in clinical presentation,
differences in the number of patients, and the different ethnic
origin of patients and controls. In fact, in the study by Palikhe
et al. (2008a,b) the allele frequencies observed in Korean
individuals differ considerably from those reported in this study
and in the 1000 genomes website for individuals of Caucasian
descent (see Table 4).
Additional clinical associations for FCER1A SNPs are the
putative association of the SNP rs2298804 with the risk of
developing systemic lupus erythematosus in a study carried
out in China (Yang et al., 2013), and the association of the
SNP rs2298805 with the risk of developing chronic spontaneous
urticaria in Chinese individuals (Guo et al., 2015). These
SNPs are ethnic-specific as they have only been identified
in Oriental individuals, but they do not occur in Caucasian
individuals according to the 1000 genomes website. Additional
clinical associations for FCER1B SNPs, all related to the SNP
rs569108, include increased risk of developing asthma in Chinese
individuals (Ramphul et al., 2014; Hua et al., 2016), and atopic
allergy in individuals from Philippines (de Guia et al., 2015).
A meta-analysis of 24 studies also supports association of the
FCER1B rs569108 SNP with asthma, although the risk seems to
be restricted to East-Asian individuals (Yang et al., 2014).
Additional clinical associations for FCER1G include a weak
effect on food sensitization, which is associated with the
interactive effect of the FCER1G rs2070901 SNP with other SNPs
in the IL4, FCER1B, and CYP24A1 genes and cord blood 25(OH)
D (Liu et al., 2011).
Strengths of this study include a high number of patients
with selective NSAID-hypersensitivity (n = 314). Moreover, the
clinical phenotypes of these patients, including the proportion
of each gender, ages, culprit drugs, and patients’ clinical
presentations correspond to those described previously
among Spaniards, thus indicating that the patient group
is representative. The number of patients and controls is
sufficiently high to obtain a good statistical power, which is
required to obtain conclusive evidence. Limitations in this study
include a low number of patients for some subgroups according
to the culprit drug (Table 2), the younger age of control
individuals as compared to patients, and the low frequency for
some of the SNPs analyzed which were, nevertheless, included in
the study because of their functional or clinical impact (Table 4).
The results of this study do not support a major association
of FCER1 genotypes in the risk of developing selective
NSAID-induced hypersensitivity. Similar genotype distributions
and allele frequencies were observed among patients and
controls, and the genotypes and frequencies correspond to those
previously reported among Spanish patients (Agúndez et al.,
2012; Amo et al., 2016). Similarly, no major differences in
histamine-metabolizing genes were observed, with the exception
of a marginally significant lower frequency of homozygous
variant genotypes corresponding to the DAO gene variation
rs10156191 among patients, which was not significant on
comparing allele frequencies (Table 6). The rest of the histamine-
metabolism SNPs did not show significant differences when
patients and controls were compared, and the genotypes and
allele frequencies corresponded with those previously reported
for Spanish individuals (García-Martín et al., 2006, 2008, 2015b;
Agúndez et al., 2012). Although some gender-related risk
associations were identified (summarized in Table 7), in all
cases these were due to differences in allele frequencies, but no
statistically significant differences for genotypes, in any of the
genetic models analyzed, were identified.
In addition to FCER1A genes, we analyzed histamine-
metabolism genes because these genes, alone or interacting with
FCER1A genes, may be involved in, and hence modulate, the
events that occur downstream of reaction triggering. Again,
to our knowledge no previous studies addressing the role
of histamine-metabolism in these genes in selective NSAID
hypersensitivity have been carried out. We previously reported
that the non-synonymous variant on the diamine oxidase
gene, rs10156191, which causes decreased metabolic capacity,
was significantly associated with cross-intolerance to NSAIDs
(OR, 1.7; 95% CI, 1.3–2.1; Pc = 0.0003; (Agúndez et al.,
2012)). Conversely, in the present study we did not find any
association of this SNP with overall selective hypersensitivity.
Regarding HNMT, it has been reported that the 939A>G
polymorphism, which lowers HNMT enzymatic activity by
decreasing HNMT mRNA stability, is associated with aspirin
intolerant chronic urticaria (Kim et al., 2009). This aside, no other
studies analyzing the possible role of gene-related histamine
metabolism in NSAID-hypersensitivity have been published.
The lack of association of selective NSAID-hypersensitivity with
functional histamine-metabolizing SNPs observed in our study
is somewhat unexpected because the culprit NSAIDs implicated
in both selective and cross hypersensitivity reactions are the
same. However, it should be taken into consideration that
the mechanisms involved in cross-intolerance are completely
different from those involved in selective hypersensitivity
(Agúndez et al., 2012) and this may explain the differences
in the linkage of histamine-related genes with the clinical
entities.
Phenotype-genotype interaction, however, may be relevant
to selective NSAID hypersensitivity: We analyzed by linear
regression the putative interaction of all genotypes as well
as phenotypic factors. The most relevant phenotypic factor
was previous history of atopy, which was strongly related to
hypersensitivity to ibuprofen. Age was related to hypersensitivity
to ibuprofen. Gender was related to the risk of developing
hypersensitivity to ASA, with men showing increased risk,
which is unexpected because drug allergy is more frequent
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in women (Doña et al., 2011). This drug-specific phenotypic
feature deserves further investigation. This study also revealed
the association of the DAO rs2052129 GG genotype with
hypersensitivity to ibuprofen and a weak association of the
DAO SNP rs10156191 in homozygosity for the detrimental
allele (TT) to an increased risk of developing selective
hypersensitivity to ASA, but not to other NSAIDs. The
fact that we observed a statistically significant association
after multiple regression with only 19 patients with selective
hypersensitivity to ASA suggests that the association is strong.
Although we should be cautious with regard to this association
because of the low number of individuals carrying the TT
genotype, further studies are warranted. Additional studies
focusing on genes known to be related to organ-specific
NSAID-induced hypersensitivity, such as hepatotoxicity (Lucena
et al., 2008, 2010; Andrade et al., 2009; Agúndez et al.,
2011), should also be conducted in subgroups of selective
responders to NSAIDs stratified according to the culprit
drug.
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